Shots:

• Biopharma companies have kept themselves afloat in the ocean of uncertainties by overcoming the hurdles of unmet demands, procurement, and maintaining a constant supply chain. However, the previous year was difficult for biopharma companies as the segment saw multiple insolvencies.
• Amidst all kinds of obstacles, many companies have sustained themselves to meet the market demands and emerged miraculously with splendid profits. This year Pfizer has secured the top position with a total revenue of $100.3B, followed by Johnson & Johnson and Roche.
• PharmaShots has compiled a list of the Top 20 BioPharma Companies based on the total revenue generated in the year 2022

Total Revenue: $19.26B

Founded Year: 2010

Total Employees: ~2,700

Headquarters: Massachusetts, United States

Market Cap: $59.63B

Stock Exchange: NASDAQ

Striving by the aim of utilizing mRNAs to develop products, Moderna is an American multinational biopharma company obligated to discover, develop, and manufacture medicines through its mRNA platform. The company's mRNA platform comprises advances across three components, i.e., mRNA, delivery, and the manufacturing process. These components are integrated, and different versions of mRNA are combined to form products. Moderna's 2022 revenue increased by 0.04% vs. 2021. In Jan'22, Moderna entered into a collaboration agreement with Carisma to develop CAR-M Therapies for the treatment of Cancer.

Total Revenue: $23.86B

Founded Year: 1668

Total Employees: ~64,200

Headquarters: Darmstadt, Germany

Market Cap: $24.75B

Stock Exchange: ETR

A science and technology company, Merck KGaA is a prominent name in developing therapeutic options targeting areas including Cardiovascular, Diabetes, Oncology, Neurology, and Immunology. Its Cardiovascular division containing Glucophage, Concor, Euthyrox, and Saizen as lead assets significantly contributed to the total revenue generated in 2022. Merck KGaA's 2022 revenue depicted an inclination of 6.56% vs. 2021. In Sep’22, Merck KGaA entered into a license agreement with Nerviano Medical Sciences to develop NMS-293 for the treatment of glioblastoma.

Total Revenue: $25.47B

Founded Year: 1923

Total Employees: ~55,200

Headquarters: Bagsvaerd, Denmark

Market Cap: $2.76B

Stock Exchange:

Considerate on discovering and developing innovative biological medicines and making them accessible to patients worldwide, Novo Nordisk focuses on a wide range of target areas, including Obesity, Rare Diseases, Chronic Diseases, Cardiovascular Diseases, Non-alcoholic Steatohepatitis, Chronic Kidney Diseases, and Alzheimer’s Diseases. Tresiba, Levemir, lnsulatard, and Victoza, among others, are developed under its Diabetes care segment. The lead contributor to the company's total revenue was Ozempic, with a sale of $2.5B. Novo's 2022 revenue increased by 0.18% vs. 2021. In Sep'22, Novo acquired Acquire Forma for a total deal value of ~$1.1B.

Total Revenue: $25.91B

Founded Year: 1885

Total Employees: ~53,100

Headquarters: Ingelheim, Germany

Market Cap: N/A

Stock Exchange: N/A

To create breakthrough therapies, Boehringer Ingelheim focuses on discovering and developing products for humans and animals. The company divides its business into segments: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Its Human Pharma business contributed 76.5% to the total generated revenue, whereas the Animal Health segment contributed 18.9%. The company's lead assets in 2022 were Jardiance ($6.26B) and Ofev ($3.46B). As a result, Boehringer’s 2022 revenue was boosted by 10.44% vs. 2021. In addition, in Oct'22, Boehringer entered into a collaboration and license agreement with Surrozen to develop SZN-413 for Retinal Diseases.

Total Revenue: $26.32B

Founded Year: 1980

Total Employees: ~25,200

Headquarters: California, United States

Market Cap: $135.29B

Stock Exchange: NASDAQ

Amgen strives to discover, develop, and manufacture the right quality human therapeutics, an American biotech company focusing on severe illness and diseases with limited treatment options. The company is currently marketing Enbrel, Prolia, Otezla, and Xgeva, among others, with Enbrel ($4.12B) and Prolia ($3.63B) being the lead contributors to the total revenue. Amgen’s 2022 revenue increased by 1.35% vs. 2021. In Aug’22, Amgen reported the acquisition of Chemocentryx for a total deal value of ~$4B.

Total Revenue: $27.28B

Founded Year: 1987

Total Employees: ~17,000

Headquarters: California, United States

Market Cap: $104.46B

Stock Exchange: NASDAQ

With target therapy areas including HIV, COVID-19, Viral Hepatitis, and Oncology, Gilead continues to advance innovative medicines to prevent and treat life-threatening diseases. The company's HIV product sales contributed $17.19B to its revenue. Its HIV segment contains products including Biktarvy, Genvoya, and Descovy, among others. Gilead’s 2022 revenue faced a recession of 0.07% vs. 2021. In Oct'22, Gilead signed an exclusive option and collaboration agreement with MacroGenics to develop MGD024 for the treatment of blood cancers, AML & MDS.

Total Revenue: $28.54B

Founded Year: 1876

Total Employees: ~21,000

Headquarters: Indianapolis, United States

Market Cap: $344.98B

Stock Exchange: NYSE

With an idea to produce quality products, Eli Lilly and Company is an American Pharmaceutical company focused on discovering, developing, manufacturing, and marketing these products. The company targets therapeutic areas, including Diabetes, Oncology, Immunology, and Neuroscience. In 2022, Trulicity ($5.69B) contributed a significant sale to the company's total revenue. Eli Lilly's 2022 revenue showed an increase of 0.81% vs. 2021. In Feb'22, Eli Lilly signed a license agreement worth ~$1.7B with ImmunoGen to develop and commercialize ADCs for the treatment of Cancer.

Total Revenue: $29.40B

Founded Year: 1781

Total Employees: ~50,000

Headquarters: Tokyo, Japan

Market Cap: $5.30B

Stock Exchange: TYO

Takeda is an R&D-driven global biopharma company that aims to bring Better Health and a Brighter Future. Takeda is focused on delivering products targeting areas including Oncology, Metabolic Disorders, Gastroenterology (GI), Neurology, and Immunology. The company's GI division was responsible for 25% of the total revenue, whereas the Rare Disease segment was responsible for 18%, PDT Immunology for 15%, Oncology for 14%, and Neuroscience for 14%. Takeda's 2022 revenue was boosted by 1.69% vs. 2021. In Dec’22, Takeda signed an agreement with Nimbus Therapeutics to acquire NDI-034858 for a value of ~$6B.

Total Revenue: $35.48B

Founded Year: 2000

Total Employees: ~69,400

Headquarters: London, United Kingdom

Market Cap: $77.61B

Stock Exchange: LON

GSK is a multinational healthcare company indulged in discovering and developing therapeutic products under its business segments, including General Medicines, Specialty Medicines, and Vaccines. In addition, the company develops products for Infectious Diseases, HIV, Immunology, Respiratory, and Oncology. GSK's 2022 revenue inclined by 6.16% vs. 2021. In May’22, GSK reported the acquisition of Affinivax for a total deal value of ~$3.3B.

Total Revenue: $43.65B

Founded Year: 1888

Total Employees: ~115,000

Headquarters: Illinois, United States

Market Cap: $181.11B

Stock Exchange: NYSE

To offer a broad portfolio of products aligned with favorable long-term healthcare trends in the developed and developing markets, Abbott Laboratories is a prominent name in developing Pharmaceuticals, Diagnostics, Medical Devices, and Nutritional Products. Its Diagnostics ($16.58B) and Medical Devices ($14.68B) added the most sale to its total revenue. Abbott’s 2022 revenue showed an increase of 1.35% vs. 2020. In Dec'22, Abbott's Eterna Spinal Cord Stimulation (Eterna SCS) system received the US FDA's approval for chronic pain.

Total Revenue: $44.35B

Founded Year: 1923

Total Employees: ~83,500

Headquarters: Cambridge, United Kingdom

Market Cap: $224.04B

Stock Exchange: LON

Driven by the idea of creating innovative medicines, AstraZeneca is a purpose-driven British-Swedish multinational company. The company is focused on developing and commercializing products in the therapy areas, including Oncology, Cardiology, Gastrointestinal Infections, and Inflammation. The company's sales from its Oncology (35%), BioPharmaceuticals (45%), Rare Disease (16%) divisions, and other medicines (4%) contributed to its overall net revenue. As a result, AstraZeneca's 2022 revenue was boosted by 18.55% vs. 2021. In addition, on Jul'22, AstraZeneca reported the acquisition of TeneoTwo for a total amount of ~$1.27B.

Total Revenue: $46.14B

Founded Year: 2004

Total Employees: ~91,573,400

Headquarters: Paris, France

Market Cap: $137.83B

Stock Exchange: NASDAQ

Sanofi is a France-based multinational biopharma company indulged in multi-faceted indications, including Oncology, Cardiovascular, Neurology, Immunology, and Inflammation. The company divides its business into pharmaceuticals, vaccines, and consumer health segments. The lead contributor to the company’s total pharmaceutical revenue ($30.29B) for 2022 was Dupixent ($8.9B). Sanofi's 2022 revenue increased by 7.42% vs. 2021. In Nov'22, Sanofi and Insilico Medicines signed a strategic research collaboration worth ~$1.2B

Total Revenue: $46.15B

Founded Year: 1887

Total Employees: ~34,300

Headquarters: New York, United States

Market Cap: $146.85B

Stock Exchange: NYSE

A global biopharmaceutical company that covers Oncology, Cardiovascular, and Immunological Diseases under its focus areas, Bristol-Myers Squibb (BMS) works with a mission to discover, develop, and deliver innovative medicines to patients who prevail over serious diseases. The company continues to operate under a single segment, out of which its lead assets for 2022 were Eliquis ($11.79B) and Opdivo ($8.25B). BMS' 2022 revenue declines by 0.49% vs. 2021. In Jun’22, BMS reported the acquisition of Turning Point Therapeutics for a total of ~$4.1B.

Total Revenue: $50.54B

Founded Year: 1996

Total Employees: ~102,000

Headquarters: Basel, Switzerland

Market Cap: $217.75B

Stock Exchange: SWX

Novartis is a multinational pharma company aiming to discover, develop, and deliver breakthrough treatments for unmet healthcare needs. The company’s primary focus is to develop products in therapy areas, including Oncology, Hepatology, Immunology, Dermatology, Musculoskeletal Diseases, Neurosciences, and Ophthalmology. Novartis comprises two global operating divisions, including Innovative Medicines and Sandoz. The company’s Immunology ($7.29B) and Hematology ($6.45B) segments generated the most sales among the Innovative Medicines. Novartis' 2022 revenue dipped by 2.09% vs. 2021. In Jun'22, Novartis signed multiple agreements with Precision to develop vivio gene editing therapies for Sickle Cell Disease and Beta Thalassemia.

Total Revenue: $54.45B

Founded Year: 1863

Total Employees: ~101,400

Headquarters: Leverkusen, Germany

Market Cap: $65.00B

Stock Exchange: ETR

Indulging in the development and commercialization of a wide range of products, Bayer is a global life science pharma company majorly focused on the Life Science, Healthcare, and Agriculture fields. Under its pharmaceutical division, the company produces products for therapy areas, including Oncology, Cardiovascular, and Kidney Diseases. Xarelto ($4.85B) and Eylea ($3.45B) were among the top contributors to the total generated revenue. Bayer's 2022 revenue inclined by 8.59% vs. 2021. In Jul'22, Bayer and Grünenthal announced the acquisition of Bayer's Nebido for $488M.

Total Revenue: $58.05B

Founded Year: 2013

Total Employees: ~50,000

Headquarters: Illinois, United States

Market Cap: $283.67B

Stock Exchange: NYSE

AbbVie is a biopharma company that aims to discover and deliver innovative medicines and solutions that address health issues across various therapeutic areas. The company has divided its products into segments: Immunology, Hematologic Oncology, Aesthetics, Neuroscience, and Eye Care. The company’s lead assets that contributed the most to its total revenue were Humira ($21.23B) and Skyrizi ($5.16B). AbbVie’s 2022 revenue was boosted by 3.31% vs. 2021. In Mar’22, AbbVie reported the completion of acquiring Syndesi Therapeutics for a total transaction value of ~1B.

Total Revenue: $59.28B

Founded Year: 1891

Total Employees: ~69,000

Headquarters: New Jersey, United States

Market Cap: $284.09B

Stock Exchange: NYSE

Delving in multi-faceted indications, including Oncology, Infectious Diseases, Respiratory, and Immunology, Merck & Co. adamantly focuses on developing products in its Pharmaceutical and Animal Health divisions. Under its Pharmaceutical division, Keytruda ($20.93B) and Gardasil 9 ($6.89B) were among the highest contributing products. Merck’s 2022 revenue increased by 21.7% vs. 2021. In Nov’22, Merck entered into a definitive agreement to acquire Imago BioSciences for ~$1.35B.

Total Revenue: $68.45B

Founded Year: 1896

Total Employees: ~1,03,600

Headquarters: Basel, Switzerland

Market Cap: $280.51B

Stock Exchange: SWX

A multi-disciplinary company focusing on Oncology, Immunology, Ophthalmology, Cardiovascular, and Respiratory, Roche is a prominent name in developing Pharmaceutical and Diagnostic Products. The company is dedicated to developing therapeutic options across areas including Oncology, Immunology, Ophthalmology, Cardiovascular, and Respiratory. In the year 2022, Roche’s Pharmaceutical sales were $49.27B, of which Ocrevus ($6.53B), Perjeta ($4.42B), and Hemlibra ($4.13B) were the highest contributors. Roche’s 2022 revenue declined by 0.61% vs. 2021. On Oct’22, Roche entered into a license agreement with HOOKIPA to develop HB-700 and arenaviral immunotherapies for treating KRAS-mutated cancers.

Total Revenue: $94.94B

Founded Year: 1886

Total Employees: ~152,700

Headquarters: New Jersey, United States

Market Cap: $430.32B

Stock Exchange: NYSE

With a series of products focused on the treatment of Cardiovascular, Oncology, Immunology, and Endocrinology, Johnson & Johnson (J&J) has held the second position among the top biopharma companies. J&J predominantly develops products under its Pharmaceutical, Medical Device, and Consumer Health division. Stelara ($9.72B), Darzalex ($7.97B), Trevicta ($4.14B), and Imbruvica ($3.78B) were the key players in the company’s pharmaceutical segment. J&J’s 2022 revenue was boosted by 1.2% vs. 2021. In Feb'22, J&J received the US FDA’s approval for Carvykti (ciltacabtagene autoleucel) to treat patients with relapsed or refractory multiple myeloma.

Total Revenue: $100.33B

Founded Year: 1849

Total Employees: ~83,000

Headquarters: New York, United States

Market Cap: $234.52B

Stock Exchange: NYSE

Pfizer is a research-based, global healthcare company that has held a significant position among biopharma companies for a considerable amount of time and is still a prominent name in the pharmaceutical business. Its business segment is divided across three broad customer groups: Primary Care, Specialty Care, and Oncology. The company focuses on discovering, developing, manufacturing, and marketing medicines and vaccines in various therapeutic areas, including Oncology, Immunology, Cardiology, Endocrinology, and Neurology. The highest contributors to the company's net revenue were Comirnaty ($37.81B) and Paxlovid ($18.93B), majorly adding to the company’s massive growth. Pfizer's 2022 revenue saw a great incline of 23.41% vs. 2021. In May'22, Pfizer reported the acquisition of Biohaven for ~11.6B.

Sources:

• Annual reports
• SEC Filings
• Press releases
• Company websites

Market Cap Source: Google finance (6^th Apr 2023)

Currency Conversion: X-Rates (6^th Apr 2023)

Note:

• All market caps were market on 6^th Apr 2023
• The revenue for Roche Increased in CHF but Decreased in USD (Due to the Currency Rate Drop)

Related Post: Top 20 BioPharma Companies based on 2021 Total Revenue